Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

181. Shared decision-making for people with asthma. (PubMed)

Shared decision-making for people with asthma. Asthma is a chronic inflammatory disease that affects the airways and is common in both adults and children. It is characterised by symptoms including wheeze, shortness of breath, chest tightness, and cough. People with asthma may be helped to manage their condition through shared decision-making (SDM). SDM involves at least two participants (the medical practitioner and the patient) and mutual sharing of information, including the patient's values (...) and preferences, to build consensus about favoured treatment that culminates in an agreed action. Effective self-management is particularly important for people with asthma, and SDM may improve clinical outcomes and quality of life by educating patients and empowering them to be actively involved in their own health.To assess benefits and potential harms of shared decision-making for adults and children with asthma.We searched the Cochrane Airways Trials Register, which contains studies identified in several

Full Text available with Trip Pro

2017 Cochrane

182. Selective citation in the literature on swimming in chlorinated water and childhood asthma: a network analysis (PubMed)

Selective citation in the literature on swimming in chlorinated water and childhood asthma: a network analysis Knowledge development depends on an unbiased representation of the available evidence. Selective citation may distort this representation. Recently, some controversy emerged regarding the possible impact of swimming on childhood asthma, raising the question about the role of selective citation in this field. Our objective was to assess the occurrence and determinants of selective (...) (OR 4.1, CI 2.1-8.0). Further, there was some evidence for citation bias: articles that confirmed the relation between swimming and asthma were cited more often (OR 1.8, CI 1.1-2.9), but this finding was not robust.There is clear evidence of selective citation in this research field, but the evidence for citation bias is not very strong.

Full Text available with Trip Pro

2017 Research integrity and peer review

183. Thora-3Di for assessing asthma in children

Thora-3Di for assessing asthma in children Thor Thora-3Di for assessing asthma in children a-3Di for assessing asthma in children Medtech innovation briefing Published: 2 October 2017 nice.org.uk/guidance/mib122 pathways Summary Summary The technology technology described in this briefing is Thora-3Di for assessing respiratory function in children with asthma. The inno innovativ vative aspects e aspects are that the measurements are taken non-invasively without the need for special breathing (...) manoeuvres, and provide information on right-versus-left lung function. The intended place in ther place in therap apy y would be instead of spirometry in secondary care in children for conditions such as asthma. The main points from the e main points from the evidence vidence summarised in this briefing are from 5 prospective, observational studies including a total of 129 patients and 139 healthy controls (young people and children) in secondary care. They show that Thora-3Di may be as effective

2017 National Institute for Health and Clinical Excellence - Advice

184. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial

Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial To determine if probiotic administration during the first 6 months of life decreases childhood asthma and eczema.We conducted a randomized, double-blind controlled trial of Lactobacillus rhamnosus GG (LGG) supplementation on the cumulative incidence of eczema (primary end point) and asthma and rhinitis (secondary end points) in high-risk infants. For the first 6 months of life, intervention infants (...) cumulative incidence of eczema was 30.9% (95% confidence interval [CI], 21.4%-40.4%) in the control arm and 28.7% (95% CI, 19.4%-38.0%) in the LGG arm, for a hazard ratio of 0.95 (95% CI, 0.59-1.53) (log-rank P = .83). At 5 years of age, the cumulative incidence of asthma was 17.4% (95% CI, 7.6%-27.1%) in the control arm and 9.7% (95% CI, 2.7%-16.6%) in the LGG arm, for a hazard ratio of 0.88 (95% CI, 0.41-1.87) (log-rank P = .25).For high-risk infants, early LGG supplementation for the first 6 months

Full Text available with Trip Pro

2017 EvidenceUpdates

185. A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults

A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Breathing retraining exercises improve quality of life in adults with asthma and at lower cost than usual care, with delivery by DVD having equivalent outcomes with lower cost than face-to-face training

2017 NIHR HTA programme

186. Reslizumab for treating severe eosinophilic asthma

Reslizumab for treating severe eosinophilic asthma Reslizumab for treating se Reslizumab for treating sev vere ere eosinophilic asthma eosinophilic asthma T echnology appraisal guidance Published: 4 October 2017 nice.org.uk/guidance/ta479 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Reslizumab for treating severe eosinophilic asthma (TA479) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee discussion 7 Patient experience 7 Current

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

187. A Roadmap for Optimizing Asthma Care Management via Computational Approaches (PubMed)

A Roadmap for Optimizing Asthma Care Management via Computational Approaches Asthma affects 9% of Americans and incurs US $56 billion in cost, 439,000 hospitalizations, and 1.8 million emergency room visits annually. A small fraction of asthma patients with high vulnerabilities, severe disease, or great barriers to care consume most health care costs and resources. An effective approach is urgently needed to identify high-risk patients and intervene to improve outcomes and to reduce costs

Full Text available with Trip Pro

2017 JMIR medical informatics

188. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. (PubMed)

Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. Asthma-COPD overlap syndrome (ACOS) or asthma-COPD overlap captures the subset of patients with airways disease who have features of both asthma and chronic obstructive pulmonary disease (COPD). Although definitions of ACOS vary, it is generally thought to encompass persistent airflow limitation in a patient older than 40 years of age with either a history of asthma or large bronchodilator reversibility (...) . ACOS affects about a quarter of patients with COPD and almost a third of patients who previously had asthma. Compared with their counterparts with asthma or COPD alone, patients with ACOS have significantly worse respiratory symptoms, poorer quality of life, and increased risk of exacerbations and hospital admissions. Whether this condition emerges after gradual shifts in airway remodelling and inflammation in a patient with COPD, as the result of noxious exposures in a patient with asthma, or even

2017 BMJ

189. Anti-IL5 therapies for asthma. (PubMed)

Anti-IL5 therapies for asthma. This review is the first update of a previously published review in The Cochrane Library (Issue 7, 2015). Interleukin-5 (IL-5) is the main cytokine involved in the activation of eosinophils, which cause airway inflammation and are a classic feature of asthma. Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed, with recent studies suggesting that they reduce asthma exacerbations, improve health-related quality of life (HRQoL) and lung (...) function. These are being incorporated into asthma guidelines.To compare the effects of therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Rα) with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments.We searched the Cochrane Airways Trials Register, clinical trials registries, manufacturers' websites, and reference lists

Full Text available with Trip Pro

2017 Cochrane

190. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. (PubMed)

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice.We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford and South Manchester, UK (...) . Patients aged 18 years or older with a general practitioner's diagnosis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treatment with a once-daily inhaled combination of either 100 μg or 200 μg fluticasone furoate with 25 μg vilanterol or optimised usual care and followed up for 12 months. The primary endpoint was the percentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase in ACT score from baseline of 3

Full Text available with Trip Pro

2017 Lancet

191. Tezepelumab in Adults with Uncontrolled Asthma. (PubMed)

Tezepelumab in Adults with Uncontrolled Asthma. In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high (...) doses of inhaled glucocorticoids.In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period. The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52.The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high dose; 146 patients) resulted

2017 NEJM

192. Association between ADAM metallopeptidase domain 33 gene polymorphism and risk of childhood asthma: a meta-analysis. (PubMed)

Association between ADAM metallopeptidase domain 33 gene polymorphism and risk of childhood asthma: a meta-analysis. This study aimed to investigate the association between ADAM metallopeptidase domain 33 (ADAM33) gene polymorphisms and the risk of childhood asthma. The relevant studies about the relationship between ADAM33 gene polymorphisms and childhood asthma were searched from electronic databases and the deadline of retrieval was May 2016. The single nucleotide polymorphisms (SNPs (...) ) of ADAM33 (rs511898, rs2280092, rs3918396, rs528557, rs2853209, rs44707, rs2280091 and rs2280089) were analyzed based on several models including the allele, codominant, recessive and dominant models. The results showed that the ADAM33 rs2280091 polymorphism in all four genetic models was associated with an increased risk of childhood asthma. Positive associations were also found between the polymorphisms rs2280090, rs2787094, rs44707 and rs528557 and childhood asthma in some genetic models. This meta

Full Text available with Trip Pro

2017 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

193. Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations

Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations Whether vitamin D reduces clinically important exacerbations of childhood asthma remains uncertain. We compared rapid to maintenance vitamin D repletion analyzed by baseline vitamin D level.Children presenting to the ED with moderate-to-severe asthma exacerbations and vitamin D levels ≤ 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily (...) ) therapy or daily oral-only therapy, and were followed for 12 months. The primary outcome was patient-initiated unplanned visits for asthma exacerbations, examined two ways: cumulative proportions with an exacerbation, and average exacerbation frequency. As this was a nutrient study, we analyzed treatment groups by quartile of baseline vitamin D level, collecting repeat levels and clinical observations at 3, 6, 9, and 12 months after enrollment.One hundred and sixteen patients in the IM+oral cohort vs

2017 EvidenceUpdates

194. The Relationship between Caesarean Delivery and Increased Risk of Developing Asthma in Childhood

The Relationship between Caesarean Delivery and Increased Risk of Developing Asthma in Childhood "The Relationship between Caesarean Delivery and Increased Risk of Deve" by Nicole Ankenbrandt < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Thesis Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Asthma prevalence nationwide is increasing. In 2011, an estimated 39.5 million individuals, or 12.9% of the population, had a diagnosis (...) of asthma, and 14% of those were children. Rate of caesarean delivery (CD) has concurrently increased over the past few decades and comprised 32.2% of all deliveries in 2014. Recent research has begun to explore for possible association between CD and later asthma development. Studies may even suggest differences in the gastrointestinal microbiome of neonates after CD and that of neonates after vaginal delivery (VD); this microbiome has been shown to affect development of a properly functioning immune

2017 Pacific University EBM Capstone Project

195. [Reslizumab (asthma) - addendum to Commission A17-02]

[Reslizumab (asthma) - addendum to Commission A17-02] Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22 [Reslizumab (asthma) - addendum to Commission A17-02] Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22 [Reslizumab (asthma) - addendum to Commission A17-02] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Reslizumab (Asthma): addendum zum auftrag A17-02; auftrag A17-22. [Reslizumab (asthma) - addendum to Commission A17-02] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 516. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Asthma; Humans

2017 Health Technology Assessment (HTA) Database.

196. Acarizax - house dust mite allergic rhinitis and allergic asthma

Acarizax - house dust mite allergic rhinitis and allergic asthma Acarizax® × Insert searchphrase to search the website Insert searchphrase to search the website > > > Acarizax® Conclusion It is IRF's overall assessment that Acarizax may be considered a relevant add-on therapy in house dust mite allergic rhinitis and allergic asthma in adults when symptomatic treatment is not adequate. Immunotherapy is a long-term treatment form, requiring high patient motivation, and after treatment

2017 Danish Pharmacotherapy Reviews

197. Asthma

Asthma Prodigy Toggle navigation Topics Specialities A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Allergies Cancer Cardiovascular Child health Drugs and devices Ear, nose and throat Endocrine and metabolic Eyes Gastroenterology Gastrointestinal Haematology Immunizations Infections and infestations Injuries Kidney disease and urology Men's health Mental health Musculoskeletal Neurological Oral health Palliative care Poisoning Pregnancy Preventative medicine Respiratory Sexual health Skin (...) and nail Women's health child health Asthma - Topic Menu Asthma: Summary Asthma is a chronic inflammatory condition of the airways. The airways are hyper-responsive and constrict easily in response to a wide range of stimuli. This may result in coughing, wheezing, chest tightness, and shortness of breath. Asthma is a common condition. The British Lung Foundation states that 5.4 million people in the UK are receiving treatment for asthma. A diagnosis of asthma should be suspected in a person

2017 Prodigy

198. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy (PubMed)

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 (...) guidelines. Pooled data from duplicate, Phase III, reslizumab versus placebo studies in patients with severe eosinophilic asthma (blood eosinophils ≥400 cells·µL-1) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced expiratory volume in 1 s (FEV1) and patient-reported outcomes. Of 953 patients, 69% (n=657) and 11% (n=106) were receiving Step 4 and Step 5 therapy, respectively. Compared with placebo, reslizumab reduced exacerbation rates

Full Text available with Trip Pro

2017 ERJ open research

199. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). (PubMed)

Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). International time trends in asthma mortality have been strongly affected by changes in management and in particular drug treatments. However, little is known about how asthma mortality has changed over the past decade. In this study, we assessed these international trends.We collated age-standardised country-specific asthma mortality rates in the 5-34 year age group from (...) the online WHO Mortality Database for 46 countries. To be included in the analysis, we specified that a country must have 10 years of complete data in the WHO Mortality Database between 1993 and 2012. In the absence of consistent and accurate asthma prevalence and prescribing data, we chose to use a locally weighted scatter plot smoother (LOESS) curve, weighted by the individual country population in the 5-34-year age group to show the global trends in asthma mortality rates with time.Of the 46 countries

2017 Lancet

200. Omega-3 fatty acids during pregnancy and asthma prevention. Are we talking here about more than just a suspect involved?

Omega-3 fatty acids during pregnancy and asthma prevention. Are we talking here about more than just a suspect involved? Ácidos grasos omega-3 durante el embarazo y prevención del asma, ¿algo más que un presunto implicado? - Evidencias en pediatría Buscando, por favor espere. Mostrar menú Gestión de biblioteca Aún no ha añadido ningún artículo a su biblioteca. | Buscar Toma de decisiones clínicas basadas en pruebas científicas Toma de decisiones clínicas basadas en pruebas científicas Mostrar (...) embarazo para realizar el ensayo clínico. Los hijos de estas mujeres forman parte de la cohorte de Copenhagen Prospective Studies on Asthma in Chilhood 2010 (COPSAC2010). Las mujeres rellenaron un cuestionario de frecuencias de consumo de alimentos y se midieron sus niveles de ácido eicosapentaenoico (EPA) y docosahexaenoico (DHA) antes de la aleatorización y una semana después del parto. Tras el parto, la cohorte se formó con 695 niños, de los que el 95,5% completaron el periodo de tres años de

2017 Evidencias en Pediatría